A Study of WVT078 in Patients With Multiple Myeloma (MM)
A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT04123418
Novartis Reference Number: CWVT078A12101
Last Update: Dec 06, 2021
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)
Interventions
Eligibility Criteria
Inclusion Criteria:
Subjects who are relapsed and/or refractory to two or more regimens including an IMID, proteasome inhibitor, and an anti-CD38 agent (if available)
Exclusion Criteria:
Use of systemic chronic steroid therapy (>or= 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment
Malignant disease other than being treated on this study
Active known or suspected autoimmune disease
Impaired cardiac function or clinically significant cardiac disease
Treatment with cytotoxic or small molecule antineoplastics or any experimental therapy within 14 days or 5 half-lives whichever is shorter
Active central nervous system involvement by malignancy or presence of symptomatic CNS metasteses
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]